Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $33M | $-40M | $-45M | $-36M | -26.0% | -14.5% | 8.7% |
| 2024 | $39M | $-46M | $-41M | $-29M | -19.9% | -6.4% | 8.3% |
| 2023 | $41M | $-44M | $-38M | $-25M | -16.3% | -6.7% | 60.9% |
| 2022 | $44M | $-25M | $-24M | $-33M | -9.3% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 33.03 |
| Operating Revenue | 33.03 |
| Cost Of Revenue | 6.22 |
| Gross Profit | 26.80 |
| Operating Expense | 72.09 |
| Research And Development | 20.82 |
| Selling General And Administration | 47.04 |
| Total Expenses | 78.31 |
| Operating Income | -45.28 |
| Total Operating Income As Reported | -51.90 |
| EBITDA | -40.14 |
| Normalized EBITDA | -33.53 |
| EBIT | -45.28 |
| Interest Income | 7.27 |
| Interest Expense | - |
| Net Interest Income | 7.27 |
| Other Non Operating Income Expenses | - |
| Other Income Expense | -6.61 |
| Interest Income Non Operating | 7.27 |
| Interest Expense Non Operating | - |
| Net Non Operating Interest Income Expense | 7.27 |
| Pretax Income | -44.63 |
| Tax Provision | 0 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -44.63 |
| Net Income From Continuing And Discontinued Operation | -44.63 |
| Net Income From Continuing Operation Net Minority Interest | -44.63 |
| Net Income | -44.63 |
| Net Income Common Stockholders | -44.63 |
| Net Income Including Noncontrolling Interests | -44.63 |
| Normalized Income | -38.02 |
| Diluted NI Availto Com Stockholders | -44.63 |
| Basic Average Shares | 106.43 |
| Diluted Average Shares | 106.43 |
| Reconciled Depreciation | 5.14 |
| Reconciled Cost Of Revenue | 5.31 |
| Total Unusual Items | -6.61 |
| Total Unusual Items Excluding Goodwill | -6.61 |
| Special Income Charges | -6.61 |
| Impairment Of Capital Assets | 3.55 |
| Restructuring And Mergern Acquisition | 3.06 |
| Depreciation Amortization Depletion Income Statement | 4.23 |
| Depreciation And Amortization In Income Statement | 4.23 |
| General And Administrative Expense | 28.12 |
| Other Gand A | 28.12 |
| Selling And Marketing Expense | 18.92 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| MaxCyte, Inc.this co. | MXCT | $132M | -2.95 | 0.77 | -26.0% | -3.23 |
| CVRx, Inc. | CVRX | $156M | - | 3.97 | -135.6% | - |
| Nano-X Imaging Ltd. | NNOX | $144M | -1.92 | 1.03 | -53.7% | -2.10 |
| Health Catalyst, Inc. | HCAT | $143M | -0.81 | 0.58 | -72.4% | -2.57 |
| TuHURA Biosciences, Inc. | HURA | $139M | -4.64 | 6.75 |
| - |
| - |
| - |
| - |
| -145.5% |
| -4.65 |
| AVITA Medical, Inc. | RCEL | $134M | -2.76 | -8.06 | 291.8% | -4.12 |
| SANUWAVE Health, Inc. | SNWV | $132M | 11.20 | 81.74 | 729.6% | 7.38 |
| The Joint Corp. | JYNT | $117M | 40.32 | 7.80 | 19.3% | 118.19 |
| Aldeyra Therapeutics, Inc. | ALDX | $106M | -3.14 | 2.40 | -76.5% | -1.63 |
| Peer Median | - | -1.92 | 3.18 | -63.0% | -2.10 | |